TEL-JAK2 Fusion Protein Expression

1

Review clinical trials related to TEL-JAK2 Fusion Protein Expression. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

Participants needed: 10
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: William ShomaliUpdated: Dec 23, 2025Locations: 4
Eligibility criteria

Has as at least 2 readings with an absolute eosinophil count >= 1,500/mm^3 in th... [+19]

Active life-threatening complication(s) from underlying eosinophilic disease (i.... [+21]